276862-85-2

Basic information

• Product Name: 1H-Pyrrolo[3,2-b]pyridine-3-carboxaldehyde (9CI)
• Synonyms: 1H-Pyrrolo[3,2-b]pyridine-3-carboxaldehyde (9CI);1H-Pyrrolo[3,2-b]pyridine-3-carbaldehyde;4-Azazindole-3-carboxyaldehyde.;1H-Pyrrolo[3,2-b]pyridine-3-carboxaldehyde, 3-Formyl-1H-pyrrolo[3,2-b]pyridine;4-Azaindole-3-carboxaldehyde;1H-Pyrrolo[3,2-b]pyridine-3-carboxaldehyde;2-b]pyridine-3-carbaldehyde;4-Azaindole-3-carboxyaldehyde
• CAS NO: 276862-85-2
• Molecular Formula: C8H6N2O
• Molecular Weight: 146.14604
• Product Categories: PYRIDINE;ALDEHYDE
• Mol File: 276862-85-2.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 361.1 °C at 760 mmHg
• Flash Point: 176 °C
• Appearance: /
• Density: 1.368
• Vapor Pressure: 2.12E-05mmHg at 25°C
• Refractive Index: 1.747
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 13.16±0.40(Predicted)
• CAS DataBase Reference: 1H-Pyrrolo[3,2-b]pyridine-3-carboxaldehyde (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrolo[3,2-b]pyridine-3-carboxaldehyde (9CI)(276862-85-2)
• EPA Substance Registry System: 1H-Pyrrolo[3,2-b]pyridine-3-carboxaldehyde (9CI)(276862-85-2)

Safety Data

• Hazardous Substances Data: 276862-85-2(Hazardous Substances Data)

Usage

General Description

1H-Pyrrolo[3,2-b]pyridine-3-carboxaldehyde (9CI) is a chemical compound with the molecular formula C10H7NO. It is a pyridine derivative with a pyrrole ring fused onto it, and it contains a carboxaldehyde group. 1H-Pyrrolo[3,2-b]pyridine-3-carboxaldehyde (9CI) is commonly used as a building block in the synthesis of pharmaceuticals and other organic compounds. It is also known for its potential pharmacological properties and has been studied for its potential use in medicinal chemistry. Additionally, it has been investigated for its role in various chemical reactions and as a key intermediate in organic synthesis. Overall, 1H-Pyrrolo[3,2-b]pyridine-3-carboxaldehyde (9CI) is an important and versatile chemical compound with a range of potential applications in the fields of pharmaceuticals, organic synthesis, and medicinal chemistry.

InChI:InChI=1/C8H6N2O/c11-5-6-4-10-7-2-1-3-9-8(6)7/h1-5,10H

Upstream product

• 272-49-1 1H-pyrrolo[3,2-b]pyridine 
• 100-97-0 hexamethylenetetramine 

Downstream Products

• 1428969-55-4 2-((3-methoxyphenyl)amino)-2-phenyl-1-(1H-pyrrolo[3,2-b]pyridin-3-yl)ethanone 
• 1196151-62-8 1H-pyrrolo[3,2-b]pyridine-3-carbonitrile 

Relevant articles and documents

Amide derivatives of 4-azaindole: Design, synthesis, and EGFR targeting anticancer agents

A series of amide derivatives of azaindole-oxazoles (11a–n) were designed and synthesized and their structures were confirmed by 1HNMR, 13CNMR and mass spectral analysis. Further, these derivatives were screened for their anticancer activity against human cancer cell lines viz; MCF7 (breast), A549 (lung) and A375 (melanoma). In vitro anticancer activity screening indicated that most of the hybrids exhibited potent inhibitory activities in a variety of cancer cell lines. Among the compounds 11d, 11e, 11f, 11j, 11k, 11l, 11m, and 11n were exhibited more potent activity than standard, in those mainly two compounds 11m and 11j were exhibited excellent activity in MCF-7 cell line with IC50 values 0.034 and 0.036 μM. Moreover, all these compounds were carried out their molecular docking studies on EGFR receptor results indicated that two potent compounds 11m and 11j were strongly binds to protein EGFR (PDB ID: 4hjo). It was found that the energy calculations were in good agreement with the observed IC50 values.

VIRAL REPLICATION INHIBITORS

The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

THERAPEUTIC AGENTS I

Compounds of formula(I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders, and pharmaceutical compositions containing them.